Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors

Nuclear Medicine and Biology

Volumn 40, Issue 6, 2013, Pages 788-794

  Dearling, Jason L J ^a,b   Barnes, Jessica W ^a,b,c,d   Panigrahy, Dipak ^a,b,c,d   Zimmerman, Robert E ^b,e   Fahey, Frederic ^a,b   Treves, S T ^a,b   Morrison, Matthew S ^f   Kieran, Mark W ^a,b,c,d   Packard, Alan B ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Department of Pediatric Oncology   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f GE HEALTHCARE   (United Kingdom)

Author keywords

v 3; Angiogenesis; Brain tumor; Cilengitide; MicroSPECT; NC100692; RGD peptides

Indexed keywords

CILENGITIDE; MARACICLATIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; VITRONECTIN RECEPTOR; CYCLOPEPTIDE; DIAGNOSTIC AGENT; TECHNETIUM 99M NC 100692; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; GLIOMA; IN VIVO STUDY; INTRACRANIAL TUMOR; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR MODEL; Α(V)Β(3); ANGIOGENESIS; ANIMAL; BRAIN TUMOR; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METHODOLOGY; MICROSPECT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RGD PEPTIDES; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; VASCULARIZATION; DIAGNOSTIC USE; PROCEDURES;

Α(V)Β(3); ANGIOGENESIS; BRAIN TUMOR; CILENGITIDE; MICROSPECT; NC100692; RGD PEPTIDES;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTEGRIN ALPHAVBETA3; MICE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84881028527     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.04.006     Document Type: Article

References (21)

1. Alghisi G.C., Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006, 13:113-135.
2. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
3. Haubner R., Wester H.J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999, 40:1061-1071.
4. Beer A.J., Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008, 27:631-644.
5. Dumont R.A., Deininger F., Haubner R., Maecke H.R., Weber W.A., Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis. J Nucl Med 2011, 52:1276-1284.
6. 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 2005, 111:3255-3260.
7. Dobrucki L.W., Tsutsumi Y., Kalinowski L., Dean J., Gavin M., Sen S., et al. Analysis of angiogenesis induced by local IGF-1 expression after myocardial infarction using microSPECT-CT imaging. J Mol Cell Cardiol 2010, 48:1071-1079.
8. 99mTc-NC100692. J Nucl Med 2006, 47:1434-1439.
9. Bach-Gansmo T., Bogsrud T.V., Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692. Clin Physiol Funct Imaging 2008, 28:235-239.
10. 99mTc-NC100692. Acta Radiol 2010, 51:40-46.
11. Indrevoll B., Kindberg G.M., Solbakken M., Bjurgert E., Johansen J.H., Karlsen H., et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett 2006, 16:6190-6193.
12. Bruning A., Runnebaum I.B. CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther 2003, 10:198-205.
13. Moore S.C.Z.R., Mellen R., Lim C.-B. Modification of a triple-detector SPECT system for small-animal imaging 2003.
14. Moore S.C.Z.R., Mahmood A., Mellen R., Lim C.-B. A triple-detector, multiple-pinhole system for SPECT imaging of rodents. J Nucl Med 2004, 45:97P.
15. Chauvenet W. A manual of spherical and practical astronomy V.II 1891, 474-566. Dover, NY, USA.
16. Liu Z., Jia B., Shi J., Jin X., Zhao H., Li F., et al. Tumor uptake of the RGD dimeric probe (99m)Tc-G(3)-2P(4)-RGD2 is correlated with integrin alpha(v)beta(3) expressed on both tumor cells and neovasculature. Bioconjug Chem 2010, 21:548-555.
17. Liu S., Hsieh W.Y., Jiang Y., Kim Y.S., Sreerama S.G., Chen X., et al. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem 2007, 18:438-446.
18. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
19. 99mTc '4+1' peptide conjugates: tuning the biodistribution by variation of coligands. Eur J Med Chem 2010, 45:3645-3655.
20. Decristoforo C., Santos I., Pietzsch H.J., Kuenstler J.U., Duatti A., Smith C.J., et al. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores. Q J Nucl Med Mol Imaging 2007, 51:33-41.
21. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem 2005, 16:1580-1588.